Astellas Collaborated with Sutro Biopharma to Advance Novel Immunostimulatory Antibody-Drug Conjugates for Cancer
- Sutro to receive a $90M up front to develop iADCs for 3 biological targets & will be eligible to receive ~$422.5M per candidate in milestones along with royalties & will lead the research & preclinical studies while Astellas will lead the clinical development
- Sutro gets an option to share costs & profits to develop & commercialize product candidates in the US. If Sutro exercises an option, the costs of co-development & co-commercialization, profits/losses will be split equally b/w the 2 companies
- The collaboration will combine Sutro’s ability with Astellas’ oncology R&D expertise to expand iADC development to treat cancer & boost anti-cancer activity, providing new options to patients who do not respond to existing cancer immunotherapies
Ref: Sutro Biopharma | Image: Astellas
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.